Analyst Price Targets — XOMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 30, 2026 10:06 am | Joseph Pantginis | H.C. Wainwright | $39.00 | $40.99 | TheFly | Xoma downgraded to Neutral from Buy at H.C. Wainwright |
| February 24, 2026 11:08 am | — | Leerink Partners | $50.00 | $25.32 | TheFly | Xoma price target raised to $50 from $45 at Leerink |
| December 12, 2025 1:44 pm | — | Stifel Nicolaus | $50.00 | $25.78 | StreetInsider | Benchmark Reiterates Buy Rating on XOMA, Ltd. (XOMA) Despite Rezolute Setback |
| December 11, 2025 3:51 pm | Joseph Pantginis | H.C. Wainwright | $97.00 | $27.00 | TheFly | Xoma price target lowered to $97 from $104 at H.C. Wainwright |
| December 11, 2025 2:57 pm | David Risinger | Leerink Partners | $45.00 | $26.51 | TheFly | Xoma price target lowered to $45 from $58 at Leerink |
| December 9, 2025 11:45 am | — | UBS | $76.00 | $30.49 | TheFly | Xoma initiated with a Buy at Lucid Capital |
Latest News for XOMA
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.
Dimensional Fund Advisors LP grew its holdings in XOMA Royalty Corporation (NASDAQ: XOMA) by 207.7% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,360 shares of the biotechnology company's stock after purchasing an additional 90,025 shares during the period.
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq:…
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's (i) 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) (the “Series A Preferred Stock”) (984,000 shares outstanding, CUSIP No.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for XOMA.
U.S. House Trading
No House trades found for XOMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.